The DOI matches its Crossref record; the references it cites are not checked yet.
1-Month or 3-Month DAPT in Women and Men at High Bleeding Risk Undergoing PCI
Open accessAbstract
Background In patients at high bleeding risk (HBR), short dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is associated with reduced bleeding and preserved ischemic protection.Objectives The aim of this study was to compare 2 short DAPT regimens, followed by aspirin monotherapy, in women and men at HBR undergoing PCI.Methods Data from 3 prospective, international studies (XIENCE Short DAPT Program) including patients at HBR undergoing PCI with fluoropolymer-based cobalt-chromium everolimus-eluting stents (XIENCE) were analyzed. The primary endpoint was the composite of death or myocardial infarction (MI) at 1 year. The key secondary endpoint was Bleeding Academic Research Consortium (BARC) types 2 to 5 bleeding.Results Among 3,364 patients, 1,154 (34.3%) were women. At 1 year, the rates of death or MI (7.6% vs 8.1%) and BARC types 2 to 5 bleeding (9.5% vs 9.2%) were similar in women and men. One-month and 3-month DAPT conferred a similar risk for death or MI in women (adjusted HR: 0.86; 95% CI: 0.54-1.36) and men (adjusted HR: 1.04; 95% CI: 0.75-1.44) (P for interaction = 0.783). In both sexes, BARC types 2 to 5 bleeding was numerically lower with 1-month DAPT, although not significant after propensity score stratification (women: 7.1% vs 11.2%; adjusted HR: 0.66; 95% CI: 0.43-1.02; men: 8.5% vs 9.7%; adjusted HR: 0.78; 95% CI: 0.57-1.06) (P for interaction = 0.378).Conclusions Among patients at HBR undergoing PCI with everolimus-eluting stents, 1- and 3-month DAPT was associated with similar risk for ischemic events irrespective of sex. In both women and men, 1-month DAPT resulted in less clinically relevant bleeding, although the bleeding risk difference was not significant after propensity score stratification.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Fluoropolymers such as PTFE, FEP, and PVDF are widely employed in catheters, tubing, and filter membranes due to low friction, biocompatibility, and sterilization resilience, which are critical for life-supporting devices like neonatal catheters, feeding lines, endotracheal tubes, ECMO circuits, and dialysis systems.
“Fluoropolymers such as PTFE, FEP, and PVDF are widely employed in catheters, tubing, and filter membranes due to their low friction, biocompatibility, and sterilization resilience, which are critical attributes for life-supporting devices like neonatal catheters, feeding lines, endotracheal tubes, ECMO circuits, and dialysis systems [24].”
From Exposure to Per- and Polyfluoroalkyl Substances (PFASs) in Healthcare: Environmental and Clinical Insights (2025) · cites this paper as [24]
Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
References 33 · Cited by 7
Research works printed but not linked: 1
- Feres, 2013, Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial, JAMA, 310, 2510
Metadata
- Authors
- Kunadian, V., Gitto, M., Vogel, B., Sartori, S., Angiolillo, D. J., Bhatt, D. L., Chehab, B. M., Feng, Y., de la Torre Hernandez, J. M., Krucoff, M. W., Maksoud, A., Mankerious, N., Oliva, A., Picon, H., Richardt, G., Sardella, G., Thiele, H., Toelg, R., Varenne, O., Vranckx, P., Windecker, S., Valgimigli, M., & Mehran, R.
- Affiliations
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- Humanitas University (IT)
- Icahn School of Medicine at Mount Sinai (US)
- University of Florida (US)
- Ascension Via Christi Hospital (US)
- Duke Medical Center (US)
- University of Kansas (US)
- Zagazig University (EG)
- Asklepios (DE)
- Policlinico Umberto I (IT)
- Hôpital Cochin (FR)
- Hasselt University (BE)
- University of Bern (CH)
- University Hospital of Bern (CH)
- Corresponding author
- Kunadian, Vijay
- Gitto, Mauro
- Mehran, Roxana
- ORCID
- Kunadian, Vijay
- Gitto, Mauro
- Vogel, Birgit
- Sartori, Samantha
- Angiolillo, Dominick J.
- Bhatt, Deepak L.
- Chehab, Bassem M.
- Feng, Yihan
- de la Torre Hernandez, Jose M.
- Maksoud, Aziz
- Mankerious, Nader
- Oliva, Angelo
- Sardella, Gennaro
- Thiele, Holger
- Varenne, Olivier
- Vranckx, Pascal
- Windecker, Stephan
- Valgimigli, Marco
- Mehran, Roxana
- Venue
- JACC: Cardiovascular Interventions
- Publisher
- Elsevier BV
- Published
- 2025-04
- Volume
- 18
- Issue
- 7
- Pages
- 866-878
- ISSN
- 1876-7605 (ISSN-L)
- 1936-8798
- OpenAlex
- W4407725039
- Cited by
- 7
- References
- 33
- Citations by year
- 2026: 2 · 2025: 5
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- JACC: Cardiovascular Interventions (publishedVersion)
- PubMed (publishedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion, other-oa)
- Newcastle University ePrints (Newcastle Univesity)
- Funders
- Abbott
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- dual antiplatelet therapy, high bleeding risk, percutaneous coronary intervention, everolimus-eluting stent, sex differences, bleeding events, myocardial infarction, mortality, aspirin monotherapy, women, propensity score stratification, ischemic protection, propensity score matching
- MeSH terms
- Everolimus, Dual Anti-Platelet Therapy, Aged, Aspirin, Chromium Alloys, Coronary Artery Disease, Drug Administration Schedule, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Platelet Aggregation Inhibitors, Prospective Studies, Prosthesis Design, Risk Factors, Sex Factors, Time Factors, Treatment Outcome, Risk Assessment, Drug-Eluting Stents, Percutaneous Coronary Intervention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
